Stockwatch: Clouds Of Controversy Darken Earnings Season
This article was originally published in Scrip
Valeant Pharmaceuticals International, Inc. was centre-stage last week, initially getting the second week of third-quarter earnings under way by reporting what the analysts from Jefferies suggested at the time was a 'solid' set of results. Those from JP Morgan described Valeant's beating of consensus estimates of sales and earnings as 'modest'. Unfortunately, that was not where the story ended.
You may also be interested in...
Investors in pharmaceutical companies appreciate details such as sales force dynamics, price-volume relationships and channel-stocking effects. Their absence can make investors wary.
Pandemic-related clinic closures and safety issues forced Novartis to trim its guidance slightly. But Roche, faced with more severe pandemic and biosimilar pressures, left January’s guidance unchanged.
With something for everyone in Johnson & Johnson’s second-quarter earnings report, a nudge upwards for full-year guidance could not disguise the jump down from January’s pre-pandemic expectations.